Your browser doesn't support javascript.
loading
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko, Krisztian; Zygoura, Panagiota; Norkin, Maxim; Tissot, Stephanie; Shakarishvili, Nicholas; Popat, Sanjay; Curioni-Fontecedro, Alessandra; O'Brien, Mary; Pope, Anthony; Shah, Riyaz; Fisher, Patricia; Spicer, James; Roy, Amy; Gilligan, David; Rusakiewicz, Sylvie; Fortis, Ekaterina; Marti, Nesa; Kammler, Roswitha; Finn, Stephen P; Coukos, Georges; Dafni, Urania; Peters, Solange; Stahel, Rolf A.
Afiliação
  • Homicsko K; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland krisztian.homicsko@chuv.ch.
  • Zygoura P; Ludwig Institute for Cancer Research, Lausanne branch, Lausanne, Switzerland.
  • Norkin M; ETOP Statistical Center, Frontier Science Foundation - Hellas, Athens, Greece.
  • Tissot S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Shakarishvili N; Ludwig Institute for Cancer Research, Lausanne branch, Lausanne, Switzerland.
  • Popat S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Curioni-Fontecedro A; Immune Landscape Laboratory, Centre Thérapies Expérimentales (CTE), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • O'Brien M; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Pope A; Lung Unit, Royal Marsden Hospital NHS Trust, London, UK.
  • Shah R; Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Fisher P; Department of Oncology, Fribourg Hospitals, Fribourg, Switzerland.
  • Spicer J; Department of Oncology, Royal Marsden Hospital NHS Trust, London, UK.
  • Roy A; Department of Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK.
  • Gilligan D; Department of Medical Oncology, Kent Oncology Centre, Maidstone, UK.
  • Rusakiewicz S; Department of Medical Oncology, Weston Park Hospital, Sheffield, UK.
  • Fortis E; Comprehensive Cancer Center, King's College London, London, UK.
  • Marti N; Department of Medical Oncology, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Kammler R; Department of Medical Oncology, Addenbrooke's Hospital, Cambridge, UK.
  • Finn SP; Immune Landscape Laboratory, Centre Thérapies Expérimentales (CTE), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Coukos G; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Dafni U; Immune Landscape Laboratory, Centre Thérapies Expérimentales (CTE), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Peters S; Translational Research Coordination, ETOP IBCSG Partners Foundation, Bern, Switzerland.
  • Stahel RA; Translational Research Coordination, ETOP IBCSG Partners Foundation, Bern, Switzerland.
J Immunother Cancer ; 11(10)2023 10.
Article em En | MEDLINE | ID: mdl-37880184
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça